Skye Bioscience, Inc. Increase (Decrease) in Accounts Payable, Trade
Skye Bioscience, Inc. (SKYE) reported Increase (Decrease) in Accounts Payable, Trade of $2.24 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableTrade · last filed 2026-08-14
- Skye Bioscience, Inc. increase (decrease) in accounts payable, trade for the quarter ending 2026-06-30 was $341.47K, a 75.05% decline year-over-year.
- Skye Bioscience, Inc. increase (decrease) in accounts payable, trade for the quarter ending 2026-03-31 was $1.90M, a 56.57% increase year-over-year.
- Skye Bioscience, Inc. increase (decrease) in accounts payable, trade for the quarter ending 2025-12-31 was -$791.57K.
- Skye Bioscience, Inc. increase (decrease) in accounts payable, trade for the quarter ending 2025-09-30 was -$397.50K.
- Skye Bioscience, Inc. increase (decrease) in accounts payable, trade for fiscal 2025 was $1.40M.
- Skye Bioscience, Inc. increase (decrease) in accounts payable, trade for fiscal 2024 was -$586.53K.
- Skye Bioscience, Inc. increase (decrease) in accounts payable, trade for fiscal 2023 was -$576.38K, a 183.74% decline from fiscal 2022.
- Skye Bioscience, Inc. increase (decrease) in accounts payable, trade for fiscal 2022 was $688.27K, a 29.00% increase from fiscal 2021.
| Period end | Increase (Decrease) in Accounts Payable, Trade 3 month | Increase (Decrease) in Accounts Payable, Trade 6 month | Increase (Decrease) in Accounts Payable, Trade 9 month | Increase (Decrease) in Accounts Payable, Trade 12 month |
|---|---|---|---|---|
| 2026-06-30 | $341.47K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $2.24M 10-Q · filed 2026-08-14 | $1.45M derived: sum of 3 quarters · filed 2026-08-14 | $1.06M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $1.90M 10-Q · filed 2026-05-11 | $1.11M derived: sum of 2 quarters · filed 2026-05-11 | $714.44K derived: sum of 3 quarters · filed 2026-05-11 | $2.08M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | -$791.57K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | -$1.19M derived: sum of 2 quarters · filed 2026-03-10 | $179.65K derived: sum of 3 quarters · filed 2026-08-14 | $1.40M 10-K · filed 2026-03-10 |
| 2025-09-30 | -$397.50K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $971.22K derived: sum of 2 quarters · filed 2026-08-14 | $2.19M 10-Q · filed 2025-11-10 | $1.98M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $1.37M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $2.58M 10-Q · filed 2026-08-14 | $2.37M derived: sum of 3 quarters · filed 2026-08-14 | $2.07M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $1.22M 10-Q · filed 2026-05-11 | $1.01M derived: sum of 2 quarters · filed 2026-05-11 | $705.54K derived: sum of 3 quarters · filed 2026-05-11 | $689.90K derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | -$210.77K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | -$510.24K derived: sum of 2 quarters · filed 2026-03-10 | -$525.88K derived: sum of 3 quarters · filed 2026-03-10 | -$586.53K 10-K · filed 2026-03-10 |
| 2024-09-30 | -$299.47K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$315.11K derived: sum of 2 quarters · filed 2025-11-10 | -$375.76K 10-Q · filed 2025-11-10 | -$840.12K derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | -$15.64K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$76.29K 10-Q · filed 2025-08-07 | -$540.65K derived: sum of 3 quarters · filed 2025-08-07 | -$534.19K derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | -$60.65K 10-Q · filed 2025-05-08 | -$525.01K derived: sum of 2 quarters · filed 2025-05-08 | -$518.55K derived: sum of 3 quarters · filed 2025-05-08 | -$191.13K derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | -$464.36K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | -$457.90K derived: sum of 2 quarters · filed 2025-03-20 | -$130.48K derived: sum of 3 quarters · filed 2025-03-20 | -$576.38K 10-K · filed 2025-03-20 |
| 2023-09-30 | $6.47K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $333.88K derived: sum of 2 quarters · filed 2024-11-07 | -$112.02K 10-Q · filed 2024-11-07 | $206.11K derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $327.42K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | -$118.49K 10-Q · filed 2024-08-09 | $199.65K derived: sum of 3 quarters · filed 2024-08-09 | $603.80K derived: sum of 4 quarters · filed 2024-08-09 |
| 2023-03-31 | -$445.90K 10-Q · filed 2024-05-10 | -$127.77K derived: sum of 2 quarters · filed 2024-05-10 | $276.39K derived: sum of 3 quarters · filed 2024-05-10 | $261.53K derived: sum of 4 quarters · filed 2024-05-10 |
| 2022-12-31 | $318.13K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-22 | $722.29K derived: sum of 2 quarters · filed 2024-03-22 | $707.43K derived: sum of 3 quarters · filed 2024-03-22 | $688.27K 10-K · filed 2024-03-22 |
| 2022-09-30 | $404.16K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $389.30K derived: sum of 2 quarters · filed 2023-11-14 | $370.14K 10-Q · filed 2023-11-14 | $976.39K derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | -$14.86K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | -$34.02K 10-Q · filed 2023-08-07 | $572.24K derived: sum of 3 quarters · filed 2023-08-07 | $481.72K derived: sum of 4 quarters · filed 2023-08-07 |
| 2022-03-31 | -$19.16K 10-Q · filed 2023-05-12 | $587.10K derived: sum of 2 quarters · filed 2023-05-12 | $496.58K derived: sum of 3 quarters · filed 2023-05-12 | $378.87K derived: sum of 4 quarters · filed 2023-05-12 |
| 2021-12-31 | $606.26K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $515.74K derived: sum of 2 quarters · filed 2023-03-31 | $398.03K derived: sum of 3 quarters · filed 2023-03-31 | $533.54K 10-K · filed 2023-03-31 |
| 2021-09-30 | -$90.52K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | -$208.23K derived: sum of 2 quarters · filed 2022-11-14 | -$72.72K 10-Q · filed 2022-11-14 | -$440.01K derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | -$117.72K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $17.80K 10-Q · filed 2022-08-15 | -$349.49K derived: sum of 3 quarters · filed 2022-08-15 | -$714.14K derived: sum of 4 quarters · filed 2022-08-15 |
| 2021-03-31 | $135.51K 10-Q · filed 2022-05-06 | -$231.78K derived: sum of 2 quarters · filed 2022-05-06 | -$596.43K derived: sum of 3 quarters · filed 2022-05-06 | -$437.41K derived: sum of 4 quarters · filed 2022-05-06 |
| 2020-12-31 | -$367.29K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | -$731.94K derived: sum of 2 quarters · filed 2022-03-28 | -$572.93K derived: sum of 3 quarters · filed 2022-03-28 | $234.53K 10-K · filed 2022-03-28 |
| 2020-09-30 | -$364.65K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | -$205.63K derived: sum of 2 quarters · filed 2021-11-10 | $601.82K 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $159.02K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-06 | $966.47K 10-Q · filed 2021-08-06 | ||
| 2020-03-31 | $807.46K 10-Q · filed 2021-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Rein Therapeutics, Inc. (RNTX) | United States | $0.063B | -1.76 |
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |